Diagnostic and prognostic value of sCD14-ST—presepsin for patients admitted to hospital intensive care unit (ICU)

Godnič, M; Stubljar, David; Skvarč, Miha; Jukić, Tomislav

doi:10.1007/s00508-015-0719-5

Cited by 37 publications

(44 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, contrary to our findings, presepsin showed a higher specificity than CRP and PCT in diagnosing sepsis [30]. Our findings differ from those of Godnic and coworkers, who reported that presepsin exhibited a higher sensitivity than CRP and PCT, whereas CRP showed a higher specificity than PCT and presepsin in diagnosing infection, with AUCs indicating that CRP tend to perform better than PCT and presepsin in detecting infection [31]. Previous meta-analyses on the diagnostic usefulness of PCT, in comparison to CRP, reported controversial and inconsistent conclusions [18,32].…”

Section: Discussioncontrasting

confidence: 86%

Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis

Ali

Elnakeeb

et al. 2016

Clinica Chimica Acta

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 86%

Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis

Ali

Elnakeeb

et al. 2016

Clinica Chimica Acta

View full text Add to dashboard Cite

“…These data agree with Godnic M et al [21] results whose findings indicated that sCD14-ST may be a promising early diagnostic and prognostic marker in septic patients. In addition, because the sCD14-ST values were especially high in severe sepsis, and there was also positive correlation between the APACHE II scores (p = 0.016) and the presepsin values reflect the immune response to bacteria in sepsis.…”

Section: Late-onset Neonatal Sepsis (Los) Is a Life-threatening Condisupporting

confidence: 83%

Presepsin as an Early Reliable Diagnostic and Prognostic Marker of Neonatal Sepsis.

Sabry¹,

Elfeky²,

Elsadek³

et al. 2016

IJAR

View full text Add to dashboard Cite

Background:-Sepsis is a common cause of morbidity and mortality among neonates, and current biomarkers for diagnosis are not adequate. The objective of the study was to assess the diagnostic and prognostic value of presepsin.Methods:-One hundred and twenty neonates were enrolled in the study; 80 cases and 40 controls. Presepsin and CRP levels were measured during 1st, 2nd& 6th days of admission for cases while were measured once for each control.Results:-Initial presepsin levels were significantly higher in group produced neonatal sepsis than in the non-septic group. At a cut off value ≥ 0.722 µg/L, Presepsin sensitivity for prediction of neonatal sepsis was 100 %, specificity 97.5%, positive predictive value (PPV) 98.7%, negative predictive value (NPV) 100%, area under curve (AUC) 0.99 with high sensitive positive correlation with sepsis (P value < 0.001). At a cut off value < 2.3 µg/L, Its prognostic sensitivity was 75.9%, specificity 72.5%, PPV 61.1, NPV 84.1 and AUC 0.76. Conclusion:-Presepsin sensitivity for early diagnosis of neonatal sepsis was 100 % with specificity 97.5%. Presepsin is an accurate biomarker for early diagnosis of neonatal sepsis. It also provides a useful tool for prediction of improving.Copy Right, IJAR, 2016,. All rights reserved.

show abstract

“…Finally, 86 studies were included after two updated searches in February 2015 and September 2016 (Fig. 1) (Abidi et al 2008; Ahmadinejad et al 2009; Al-Nawas et al 1996; Anand et al 2015; Balc et al 2003; Barati et al 2010; Battista et al 2016; Bell et al 2003; Beqja-Lika et al 2013; Carpio et al 2015; Castelli et al 2004; Clec’h et al 2006; de Pablo et al 2013; Dorizzi et al 2006; Du et al 2003; Endo et al 2012; Farag et al 2013; Feng et al 2012; Gaini et al 2006; Garnacho-Montero et al 2014; Gerrits et al 2013; Giamarellos-Bourboulis et al 2008; Gibot et al 2004; Godnic et al 2015; Guven et al 2002; Han et al 2016; Harbarth et al 2001; Hoenigl et al 2013; Hou et al 2012, 2016; Hsu et al 2011; Ishikura et al 2014; Ivancevic et al 2008; Jekarl et al 2013, 2014; Jiang et al 2015; Kim and Zhang 2012; Kofoed et al 2007; Latour-Perez et al 2010; Lewis et al 2015; Li et al 2013a; Lin et al 2015; Matera et al 2013; Mat-Nor et al 2016; Mearelli et al 2014; Meynaar et al 2011; Miglietta et al 2015; Miller et al 1999; Muthiah et al 2007, Naeini and Montazerolghaem 2006; Oshita et al 2010; Papadimitriou-Olivgeris et al 2015; Ratzinger et al 2013; Reichsoellner et al 2014; Righi et al 2014; Rivera-Chavez and Minei 2009; Rogina et al 2014; Romualdo et al 2014; Ruiz-Alvarez et al 2009; Sakr et al 2008; Scherpereel et al 2006; Schulte et al 2011; Selberg et al 2000; Seok et al 2012; Shozushima et al 2011; Sierra et al 2004; Su et al 2012, 2013; Sungurtekin et al …”

Section: Resultsmentioning

confidence: 99%

Biomarkers for diagnosis of sepsis in patients with systemic inflammatory response syndrome: a systematic review and meta-analysis

et al. 2016

View full text Add to dashboard Cite

BackgroundSepsis is one of the most common diseases that seriously threaten human health. Although a large number of markers related to sepsis have been reported in the last two decades, the diagnostic accuracy of these biomarkers remains unclear due to the lack of similar baselines among studies. Therefore, we conducted a large systematic review and meta-analysis to evaluate the diagnostic value of biomarkers from studies that included non-infectious systemic inflammatory response syndrome patients as a control group.MethodsWe searched Medline, Embase and the reference lists of identified studies beginning in April 2014. The last retrieval was updated in September 2016.ResultsUltimately, 86 articles fulfilled the inclusion criteria. Sixty biomarkers and 10,438 subjects entered the final analysis. The areas under the receiver operating characteristic curves for the 7 most common biomarkers, including procalcitonin, C-reactive protein, interleukin 6, soluble triggering receptor expressed on myeloid cells-1, presepsin, lipopolysaccharide binding protein and CD64, were 0.85, 0.77, 0.79, 0.85, 0.88, 0.71 and 0.96, respectively. The remaining 53 biomarkers exhibited obvious variances in diagnostic value and methodological quality.ConclusionsAlthough some biomarkers displayed moderate or above moderate diagnostic value for sepsis, the limitations of the methodological quality and sample size may weaken these findings. Currently, we still lack an ideal biomarker to aid in the diagnosis of sepsis. In the future, biomarkers with better diagnostic value as well as a combined diagnosis using multiple biomarkers are expected to solve the challenge of the diagnosis of sepsis.Electronic supplementary materialThe online version of this article (doi:10.1186/s40064-016-3591-5) contains supplementary material, which is available to authorized users.

show abstract

Diagnostic and prognostic value of sCD14-ST—presepsin for patients admitted to hospital intensive care unit (ICU)

Abstract: CD64 index, CRP and sCD14-ST served as good parameters to determine possible infection in patients that needed intensive care after major procedures. Values of PCT were the only ones to predict SIRS severity and could distinguish between sepsis and severe sepsis or septic shock.

Cited by 37 publications

References 35 publications

Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis

Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis

Presepsin as an Early Reliable Diagnostic and Prognostic Marker of Neonatal Sepsis.

Biomarkers for diagnosis of sepsis in patients with systemic inflammatory response syndrome: a systematic review and meta-analysis

Contact Info

Product

Resources

About